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 Abstract. The purpose of the study was to evaluate the
antitumor activity and the safety of paclitaxel combined with
gemcitabine and cisplatin in patients affected by advanced
transitional cell carcinoma of the urothelium (TCC). Eighty-five
patients affected by advanced TCC and measurable disease
were randomized to receive either paclitaxel at dosage of
70 mg/m2, gemcitabine 1000 mg/m2 and cisplatin 35 mg/m2 on
days 1 and 8 every 3 weeks (GCP) or gemcitabine 1000 mg/m2
on days 1, 8, 15 and cisplatin 70 mg/m2 on day 2 every 4
weeks (GC). All enrolled patients were considered evaluable
for response and toxicity (intention to treat). The observed
response rate was 43% for GCP and 44% for GC combination,
respectively. Median time to treatment failure was 32 weeks
for GCP and 26 weeks for GC and overall survival 61 vs 49
weeks, respectively (p-value not significant). Grade 3-4 neutro-
penia was observed in 49% of patients treated with GCP vs
35% of those treated with GC (P=0.05) and grade 3-4
thrombocytopenia was observed in 36% of GCP treated
patients as compared to 21% of those treated with GC
(P=0.01). Seven patients over 70 years old or with poor PS
were removed from the study: 6 patients from GCP group
(2 toxic deaths, 2 grade 4 myelotoxicity and 2 grade 3
asthenia) and 1 from GC group was lost to follow-up after the
first cycle. The combination of paclitaxel, gemcitabine and
cisplatin is effective in the treatment of TCC. However, the
addition of paclitaxel to the combination of gemcitabine plus
cisplatin seems to increase toxicity, therefore it seems not
suitable for poor PS patients and those over 70 years old.
Larger and more powered studies are needed to exactly define
the role of paclitaxel in this combination.
Introduction
Methotrexate, vinblastine, doxorubicin, and cisplatin (M-
VAC) or cisplatin, methotrexate, and vinblastine (CMV)
have been considered as the standard treatment in patients
affected by advanced transitional cell carcinoma of the
urothelium (TCC) (1,2). These regimens, although effective,
were associated with a high rate of toxicity, including
neutropenia with its infectious complications, significant
mucositis, nausea and vomiting, renal, cardiac, and neuro-
toxicity. Indeed, deaths due to toxicity have been reported to
be as high as 3-4% even in centres experienced in the use of
M-VAC (3-6).
Gemcitabine (Gemzar; Eli-Lilly and Company,
Indianapolis, IN), offers proven activity against a range of
solid tumors (7-10). In particular, in metastatic urothelial
cancer, gemcitabine alone yielded response rates of 23-29%
with a complete response rate of 4-13%, in both previously
treated and untreated patients (11). The good activity and
toxicity profile of single-agent gemcitabine and its synergism
with cisplatin in pre-clinical models (12) have led to the
development of this combination in advanced TCC. Recently,
von der Maase et al (13) have published a large multinational
phase III trial comparing M-VAC regimen with gemcitabine
plus cisplatin (GC), with a total of 405 patients accrued. The
final results showed that the two regimens were similar in
terms of response rate, time to progression and survival.
However, the GC combination showed a better safety profile
and tolerability than M-VAC. Based on these data, GC
combination appeared to be a standard alternative treatment
in patients affected by advanced TCC.
Paclitaxel (Taxol), a drug that stabilizes microtubles and
promotes their assembly resulting in an M-phase cell-cycle
arrest (14), has been shown to be active against TTC both in
preclinical as well in clinical studies (Niell HB et al, Proc
Am Assoc Cancer Res 34: abs. 1207, 1993) (15,16). The
combination of paclitaxel with cisplatin was also tested in at
least 3 clinical trials: response rates of 62-72% and complete
response rates of 10-34% have been reported (Murphy BA,
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et al, Proc Am Soc Clin Oncol 15: abs. 617, 1996) (Dreicer R,
et al, Proc Am Soc Clin Oncol 17: abs. 1233, 1998) (Burch
PA, et al, Proc Am Soc Clin Oncol 18: abs. 1266, 1999). The
aim of this study was to evaluate the activity of the
combination of cisplatin, gemcitabine and paclitaxel in
advanced TCC patients.
Materials and methods
The primary objective of this study was to define the
investigator-assessed objective response rate, while the
secondary objectives were to evaluate the safety and
tolerability of these chemotherapy regimens. Eighty-five
patients, from 11 Italian cancer centres, were randomised to
receive either paclitaxel at dosage of 70 mg/m2, gemcitabine
1000 mg/m2 and cisplatin 35 mg/m2 on days 1 and 8 every
3 weeks (arm A or experimental arm), or gemcitabine 1000
mg/m2 on days 1, 8, 15 plus cisplatin 70 mg/m2 on day 2
every 4 weeks (arm B or control arm). A maximum of 6
cycles were administered. Each patient remained in the study
until disease progression was noted or until either the patient
or investigator thought that it was in the patient's best interest
to discontinue. The treatment was stopped in all cases of
intolerable toxicity. The patients had histologically proven
metastatic or unresectable transitional cell carcinoma of the
urinary tract. Those who had received previous chemotherapy
for advanced disease were excluded from the study.
Nevertheless, patients who underwent cystectomy may have
received adjuvant or neoadjuvant chemotherapy at that time
but chemotherapy had to be concluded 1 year before study
entry. Other eligibility criteria included written informed
consent, Eastern Cooperative Oncology Group (ECOG)
performance status ≤2 and adequate bone marrow reserve,
defined by a white blood count of 3,500 µl or greater, platelet
count >100,000 µl and haemoglobin level >10 gm/dl. Study
exclusion criteria were: inadequate liver function defined by
bilirubin >1.5 mg/dl, prothrombin and partial thromboplastin
time >1.5-fold normal, transaminase >3-fold normal,
inadequate renal function defined by creatinine >1.5 mg/dl
with calculated creatinine clearance <50 ml per min and
hypercalcemia, or the diagnosis of pure squamous carcinoma
or adenocarcinoma of the urothelium. Disease evaluation in
all cases included tomography or magnetic resonance image
(MRI) of the lesions, although accurate ultrasound was
considered sufficient for hepatic metastases evaluation.
Moreover, bone scan was not considered useful for evaluating
bone lesions which were evaluated by X-rays or MRI.
Responses were reviewed by an internal review board of
radiologists and medical oncologists not participating in the
study. The protocol was approved by the Ethics Committee
of the Oncology Institute of Bari which was the coordinating
centre of the study. With regard to dose reduction guidelines,
in case of an absolute granulocyte count of 1,000-1,500x106 l
and or platelet count between 110,000-75,000 ml on
treatment day, patients had a 50% dose reduction of
gemcitabine and paclitaxel with full dose of cisplatin. In case
of lower values, treatment was delayed until recovery. In
addition, grade 3-4 WHO non-haematological toxicity other
than nausea, vomiting or alopecia required a 25% dose
reduction of each drug as well as complete recovery before
therapy restoration. After the completion of two treatment
courses, all patients underwent re-evaluation, including a
repeat of all previously abnormal radiological studies. Patients
were assigned a response category using standard World
Health Organization (WHO) definitions. A complete response
required the complete resolution of all clinical evidence of a
tumor, as determined by two observations not <4 weeks apart.
A partial response required a decrease ≥50% in the size of
measurable lesions, as determined by the sum of the greatest
tumor dimensions, with no new lesions appearing. Stable
disease was defined as a decrease <50% or an increase <25%
in tumor measurements, with no new lesions appearing.
Progressive disease occurred when measurable lesions
increased in size by >25%, evaluable lesions worsened or
new lesions appeared.
Statistical considerations. The primary endpoint of this study
was to evaluate the response rate and safety of the combination
of paclitaxel, gemcitabine and cisplatin. We chosen a phase II
randomised design in order to avoid selection bias. Therefore,
the second arm or control arm constituted the combination of
gemcitabine plus cisplatin was considered the standard arm.
The two arms proceeded independently and a sequential 2-
step statistical test of Gehan to define the number of patients
required to detect the activity of the treatment could be applied
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Table I. Patient characteristics.
–––––––––––––––––––––––––––––––––––––––––––––––––
Demographics GCP GC
–––––––––––––––––––––––––––––––––––––––––––––––––
Entered/evaluable 42 43
Early drop out: 6 1
Grade 4 myelotoxicity 4 -
Grade 3 asthenia 2 -
Lost to follow up - 1
Male/female 40/2 41/2
Median age (range) 69 (48-76) 68 (49-76)
Performance status:
0 18 19
1 16 18
2 8 6
Prior treatment:
(Neo)/adjuvant 4 5
Primary tumor site:
Bladder 41 40
Renal pelvis 1 3
Metastatic sites:
Locally advanced only 10 14
Nodal/soft tissue only 9 10
Liver 8 6
Bone + nodal 7 5
Lung 8 7
Peritoneal carcinomatosis - 1
–––––––––––––––––––––––––––––––––––––––––––––––––
(17). After the first 16 patients were randomised to the
experimental arm, at least 7 responses were required to
proceed to the next accrual target of 43 cases to ensure with
95% confidence that a true response was at least 35%. We used
the Kaplan-Meier method to analyse time to progression and
overall survival. Confidence intervals (CI) of the response rates
were calculated using the method described by Simon (18).
Because of the scant number of patients in each arm of the
study, no direct comparisons in activity, but only single arm
evaluation of tolerability is allowed.
Results
Eighty-five patients entered on this phase II randomised trial
from December 1999 to January 2002 by 11 Italian centres.
The characteristics of patients who received at least one cycle
of chemotherapy are compared in Table I. There were no
significant differences in age, gender, performance status,
stage and metastatic site involved between the two groups.
The responses of patients who were treated with each of the
two regimens are illustrated in Table II. Of 42 patients treated
with GCP, 4 patients discontinued treatment after the first
cycle because of grade 4 life-threatening myelotoxicity
which caused 2 toxic deaths due to neutropenic sepsis and 2
patients discontinued after the second cycle due to grade 3
asthenia. On the other hand, no patient suffered from life-
threatening toxicity in the GC arm but 1 patient was lost to
follow up after the first cycle. If we consider all randomised
patients as evaluable for response and toxicity on an intent to
treat basis, 5 complete responses plus 13 partial responses
were recorded in GCP arm for an overall response rate of
43%, whereas 3 complete responses plus 16 partial responses
for an overall response rate of 44% for GC arm were
observed, respectively (P= N.S.). The 95% confidence
intervals for the response rate were 23-63% in GCP arm and
28-60% in GC arm. An additional 12 patients for GCP arm
(29%) and 10 patients for GC arm (23%) had stable disease
and 12 (29%) and 14 (33%) patients progressed respectively.
The median time to treatment failure was 32 (range 2-40+)
and 26 (range 2-43+) weeks, and median survival was 61
(range 2-85) and 49 (range 2-72) weeks for GCP and GC
treated patients, respectively (Figs. 1 and 2).
Toxicity. The three-drug regimen (GCP) was more myelotoxic
than the two-drug regimen (GC) as illustrated in Table III.
Grade 3 and 4 leukopenia were less frequent with the two-
drug combination (35 vs 49% P=0.053) and also thrombo-
cytopenia was significantly less frequent with the two-drug
combination (21 vs 36% P=0.018). No significant differences
were observed in G 3-4 anaemia (24 vs 19.6% P=0.73). The
non-haematological toxicities are illustrated in Table IV.
Overall, considering all toxicity grades, the GC regimen was
less toxic as compared to GCP regimen with regard to infection
(5 vs 9%), asthenia (2 vs 15%), mucositis (2 vs 12%), diarrhoea
(0 vs 7%), neurotoxicity (7 vs 17%), renal (10 vs. 12%). No
differences were observed in the incidence of nausea and
vomiting (47 vs 40% respectively) and ototoxicity (5 vs 2%
respectively). There were two treatment related deaths in GCP
arm which occurred after the first cycle in 2 patients over 70
and with poor PS, both due to sepsis. Haematological growth
factors (G-CSF) were used in 23 patients of GCP arm (55%)
and in 11 (26%) patients of GC arm in order to overcome
haematological toxicity. However, most of G-CSF were given
prophylactically to patients with an older age or poor PS in
order to avert grade IV neutropenia. This happened particularly
after we recorded the two toxic deaths.
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Table II. Response rates.
–––––––––––––––––––––––––––––––––––––––––––––––––
GCP GC
–––––––––––––––––––––––––––––––––––––––––––––––––
No evaluable patients 42 43
Complete response 5 (12%) 3 (7%)
Partial response 13 (31%) 16 (37%)
Stable disease 12 (29%) 10 (23%)
Progressive disease 12 (29%) 14 (33%)
Overall response rate 43% 44%
95% CI 23-63 28-60
Median time to progression 32 weeks 26 weeks
Median survival 61 weeks 49 weeks
–––––––––––––––––––––––––––––––––––––––––––––––––
Figure 1. GCP vs GC in bladder cancer: a phase II randomised study: time to
treatment failure.
Figure 2. GCP vs GC in bladder cancer: a phase II randomised study: overall
survival.
Discussion
For more than a decade the M-VAC regimen has been the
gold standard chemotherapy in bladder cancer, albeit that the
toxicity associated with this therapy hampered its use in many
of the typical elderly patients with metastatic disease. More
recently, the randomised trial comparing the combination of
gemcitabine, cisplatin (GC) with M-VAC in 405 patients, has
showed similar efficacy for the two regimens with respect to
response, time to progression, and overall survival, but with
much lower toxicity associated to GC. Based on this superior
risk-benefit ratio, the two-drug combination GC became the
new standard of care in patients with locally advanced and
metastatic urothelial cancer. However, the development of
more effective regimens for patients with metastatic bladder
cancer remains a priority. The Spanish Oncology Genitourinary
Group conducted a phase I/II trial combining gemcitabine,
cisplatin and paclitaxel (19). Fifteen patients were entered at
4 different dose levels in the phase I part of the study. Dose-
limiting toxicity was grade 2 and 3 asthenia at dose level 4.
The recommended doses for the phase II part of the study
were gemcitabine, 1000 mg/m2, on days 1 and 8; paclitaxel,
80 mg/m2 as a 3 h infusion, on days 1 and 8; and cisplatin, 70
mg/m2, on day 1, every 21 days. An additional 46 patients
were entered in the phase II portion, resulting in a total of 49
patients at the specific dose level (3 patients from the phase I
part). A total of 58 patients were evaluable for response, with
an overall response rate of 78% and a CR rate of 28%.
Responses were observed at all dose levels and in all disease
sites. The median survival for the phase I portion of the study
was 24 months, subsequently reduced to 15.8 months when
enough follow-up was available for the entire group of the
patients (20). However, this regimen was very toxic. In fact,
full dose was possible only in 15/46 patients (32.6%), 9
patients were removed from the study for toxicity (1 death
due to neutropenic sepsis, 1 because of haematological
toxicity, 3 because of renal toxicity and 4 because of non-
haematological toxicity). Moreover, G-CSF were given to 18
patients in 42 cycles. Another triple combination was reported
by Bajorin et al (21) who combined ifosfamide, 1.5 g/m2
daily, on days 1-3; paclitaxel, 200 mg/m2 in 3 h on day 1; and
cisplatin, 70 mg/m2 on day 1 with granulocyte colony
stimulating factors administered during each 28-day
treatment cycles. A total of 44 patients were evaluable for
response, with an overall response rate of 68% and a CR rate
of 23%. The median survival was 20 months. Toxicity seemed
to be independent of whether the treatment was recycled at 3
or 4 weeks. The most important grade toxicity was myelo-
suppression. Seven patients (16%) had neutropenic fever.
Non-haematological toxicities included grade 3 renal
insufficiency (11%), and grade 3 neuropathy occurred in 9%
of the patients. In a study by Hussain et al (22), 49 patients
received gemcitabine 800 mg/m2 on day 1 and 8, paclitaxel
200 mg/m2 in 3 h on day 1 and carboplatin AUC 5 on day 1
every 21 days. Prior chemotherapy for metastatic disease was
not allowed. The overall response rate for 47 evaluable
patients was 68% with a CR rate of 32%. Responses were
observed in all sites and within 15 of 22 patients with
visceral metastases. The median survival was 14.7 months.
The major toxicities were grade 3-4 neutropenia and grade 3-4
thrombocytopenia in 73 and 43% of patients, respectively.
There were no toxicity related deaths.
In this study we have treated 42 patients with a triple
combination (gemcitabine, paclitaxel and cisplatin) and 43
patients with a doublet of gemcitabine/cisplatin in randomised
fashion. The phase II randomised design of the study was
chosen in order to avoid selection bias that often influence
results of phase II studies. However, the type of study chosen
and the number of patients in each treatment arm do not
allow to draw any definitive conclusion regarding responses
and survival. On the other and, this type of study is planned
to give information of feasibility of a new regimen with
particular regard to safety. In this regard, the response and
toxicity data of the GC arm are comparable to those reported
in a number of studies in literature, therefore we can assume,
because of the randomised phase II trial, that cases also in the
GCP arm were not a particularly selected patient group.
Noteworthy in this study is the outcome of patients treated
with the triple combination. This combination was derived
from that used by Bellmunt (19) and modified splitting
cisplatin in 2 doses of 35 mg/m2 given on days 1 and 8
instead of the 70 mg/m2 on day 1 of the original Bellmunt
schedule. Moreover, paclitaxel dosage was slightly decreased
to 70 mg/m2 on days 1 and 8 (instead of 80 mg/m2) in the
hope of further reduction in the toxicity of the Spanish
regimen, however, without success. In fact, in the Bellmunt
study, a full dose of drugs was administered only in 15/46
patients in the phase II part of the study (32.6%) and 9
patients were removed from the study for toxicity, moreover
G-CSF was given to 18 patients and 42 cycles. In our study,
despite the schedule changes, grade 3-4 leukopenia was
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Table III. Hematological toxicity. 
–––––––––––––––––––––––––––––––––––––––––––––––––
Toxicity GCP (107 cycles) GC (121 cycles)
–––––––––––––––––––––––––––––––––––––––––––––––––
Grade G 3 G 4 G 3 G 4
Leukopenia 20% 29% 18% 17%
Thrombocytopenia 15% 21% 7% 14%
Anemia 9% 11% 10% 14%
–––––––––––––––––––––––––––––––––––––––––––––––––
Table IV. Non-hematological toxicity.
–––––––––––––––––––––––––––––––––––––––––––––––––
Toxicity                   GCP (42 patients)       GC (43 patients)
–––––––––––––––––––––––––––––––––––––––––––––––––
Grade (%) 1-2 3-4 1-2 3-4 
Infection 1 (2) 3 (7) 2 (5) -
Nausea/vomiting 10 (23) 7 (17) 9 (21) 11 (26)
Asthenia 4 (10) 2 (5) 1 (2) -
Mucositis 2 (5) 3 (7) 1 (2) -
Diarrhea 3 (7) - - -
Neurotoxicity 5 (12) 2 (5) 3 (7) -
Renal 3 (7) 2 (5) 2 (5) 2 (5)
Ototoxicity - 1 (2) - 2 (5)
–––––––––––––––––––––––––––––––––––––––––––––––––
observed in 49% of cycles, grade 3-4 thrombocytopenia in
36% of cycles and 2 patients although older than 70 and with
poor PS died of toxicity. Moreover, another significant
nonhematological toxicity (already reported by Bellmunt)
was asthenia which was observed in 6 patients and caused
refusal to continue in 2 patients. The conclusion is that the
triple regimens are more toxic than the doublets.
With regard to the activity of this regimen, our data does
not support the enthusiastic responses of Bellmunt et al. In
fact, we observed 3 complete and 15 partial responses among
42 treated patients for an overall response rate of 43% which
is significantly lower than that reported by Bellmunt et al.
The possible reasons for this response default may be the
older median age of our patients (69 vs 66) and other pre-
treatment factors (i.e. patient selection) which may have an
impact on the outcome in terms of response and survival.
In conclusion, the combination of gemcitabine, paclitaxel
and cisplatin in this phase II randomised study did not
achieve results superior to those reported in literature in a
number of studies with a gemcitabine/cisplatin comprising
doublet. On the other hand, the toxicity was relevant
confirming the previous reports with similar combinations.
However, only the results of the large randomised phase III
trial still ongoing by EORTC, comparing GCP vs GC in a
large number of patients, will definitively state if the addition
of paclitaxel to gemcitabine/platinum will really improve the
response and survival of these patients, or only add toxicity,
abolishing any potential advantage over M-VAC.
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